Conte Lisa A - Sep 13, 2021 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role: CEO and President, Director
Signature: /s/ Steven R. King, Attorney-in-Fact
Stock symbol: JAGX
Transactions as of: Sep 13, 2021
Transactions value $: $20,000
Form type: 4
Date filed: 3/30/2022, 09:26 PM
Next filing: Apr 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAGX	Common Stock	Purchase	$20K	+7.97K	+22765.71%	$2.51	8K	Sep 13, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAGX	Restricted stock units	Award	$0	+606K		$0.00	606K	Mar 28, 2022	Common Stock	606K		Direct	F2, F3, F4, F5
transaction	JAGX	Restricted stock units	Award	$0	+25K		$0.00	25K	Mar 28, 2022	Common Stock	25K		Direct	F2, F3, F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
F2	Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F3	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4	The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.
F5	The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.
F6	The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe.